

**In-Vitro Anticancer Activity of A Siddha Poly Herbal Formulation-
Narasimha Legiyam against Hela Cervical Cancer Cell Lines**

G. Yogalakshmi, H. Nalini sofia, S.Mohan
Dept.ofMaruthuvam, National Institute of Siddha, Chennai
drgyoga2521@gmail.com

Cancer is a second leading cause of death globally and is responsible for 9.6 million deaths in 2018. Globally 1 in 6 deaths is due to cancer. Presently various therapies are available for the treatment of cancer such as chemotherapy, radiotherapy, immune modulation and surgery etc. Besides these expensive therapies, phytotherapy plays a significant role for the treatment of cancer. The formulations in Siddha system act on many biochemical pathways and it tends to have reduced side effects due to its anti-oxidant property. The main aim of the study is to screen the Poly Herbal formulation “*Narasimha Legiyam*” for its In-vitro Anti-Cancer activity against HeLa cell line in MTT Assay. All the herbal ingredients including honey and ghee added in *Narasimha Legiyam* has been proved to have Anti-cancer activity in various cell line studies. Hence the formulation *Narasimha Legiyam* indicated for cervical cancer in SKM Therapeutic index might have Anti-cancer activity. Serial dilutions of test formulation (10, 50, 100 and 200 µg/ml) were prepared using DMSO. The in vitro determinations of anti-proliferative effects of the test formulation have been performed by MTT assay. Least viability of cell was observed at the concentration of 200µg/ml shows $56.03 \pm 3.15\%$, followed by this at 100µg/ml and 50 µg/ml shows 68.47 ± 4.782 , $82.24 \pm 4.133\%$ similarly 10 µg/ml shows $93.11 \pm 3.184\%$ cell viability in MTT assay. The corresponding IC₅₀ value was found to be $219.7 \pm 5.704 \mu\text{g/ml}$. It was concluded from the result of the present study that the formulation *Narasimha Legiyam* possesses promising anti-cancer activity against HeLa cell line which further have to be confirmed through In vivo model.

Key Words: Siddha, *Narasimha Legiyam*, Anti-Cancer activity, Cervical Cancer.